Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

Background Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cell responses. However, OV treatment negatively alters the cancer-immune set point in tumors to attenuate the antitumor immune response, which suggests the necessity o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jun Zhang, Min Zhao, Ningshao Xia, Yong Luo, Fei Ju, Chaolong Lin, Xian Jia, Zilong Xu, Rui Tian, Yanhua Lin, Yating Chang, Xiaoxuan Huang, Shaopeng Li, Wenfeng Ren, Yaning Qin, Mengqin Yu, Jizong Jia, Jinle Han, Wenxin Luo, Guo Fu, Xiangzhong Ye, Chenghao Huang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2022-06-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/10/6/e004762.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!